Recent progress in the management of pediatric chronic myeloid leukemia

Area of Science:

• Hematology
• Pediatric Oncology
• Molecular Biology

Background:

• Chronic myeloid leukemia (CML) is a rare myeloproliferative neoplasm in children, primarily driven by the BCR::ABL1 gene.
• This genetic abnormality in hematopoietic stem cells results in leukocytosis, platelet proliferation, and splenomegaly.
• Tyrosine kinase inhibitors (TKIs) have emerged as a primary treatment, largely supplanting hematopoietic cell transplantation for chronic-phase CML.

Purpose of the Study:

• To review current TKI-based management strategies for pediatric CML.
• To assess the clinical efficacy of TKIs in pediatric CML, an area less studied than in adults.
• To discuss the potential for TKI discontinuation in children to mitigate long-term adverse events.

Main Methods:

• Literature review of existing studies and clinical guidelines.
• Analysis of TKI efficacy and safety data specifically in pediatric CML patients.
• Exploration of TKI discontinuation protocols and their implications.

Main Results:

• TKIs are the established first-line therapy for pediatric CML, offering improved outcomes.
• Data on TKI efficacy in children is less extensive than in adults, necessitating careful monitoring.
• Adverse events, including growth impairment, are significant concerns in pediatric patients undergoing TKI therapy.

Conclusions:

• TKI therapy is the standard of care for pediatric CML, requiring tailored management strategies.
• Further research is needed to optimize TKI treatment protocols and understand long-term outcomes in children.
• Investigating TKI discontinuation is crucial for improving the quality of life and minimizing side effects in pediatric CML survivors.